For help on how to get the results you want, see our search tips.
6 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Withdrawn applications Remove Withdrawn applications filter
Summaries of opinion Remove Summaries of opinion filter
Paediatric investigation plans Remove Paediatric investigation plans filter
Direct healthcare professional communication Remove Direct healthcare professional communication filter
Categories
Human Remove Human filter
Medicine type
Additional monitoring Remove Additional monitoring filter
Biosimilar Remove Biosimilar filter
Patient safety
Yes Remove Yes filter
-
List item
Human medicine European public assessment report (EPAR): Lemtrada (updated)
alemtuzumab, Multiple Sclerosis
Date of authorisation: 12/09/2013,
, 
, Revision: 11, Authorised, Last updated: 25/03/2021
-
List item
Human medicine European public assessment report (EPAR): Gilenya
fingolimod hydrochloride , Multiple Sclerosis
Date of authorisation: 17/03/2011,, , Revision: 28, Authorised, Last updated: 04/02/2021
-
List item
Human medicine European public assessment report (EPAR): Xarelto
rivaroxaban, Arthroplasty, Replacement, Venous Thromboembolism
Date of authorisation: 30/09/2008,, , Revision: 33, Authorised, Last updated: 02/02/2021
-
List item
Human medicine European public assessment report (EPAR): Xeljanz
tofacitinib citrate, Arthritis, Rheumatoid
Date of authorisation: 21/03/2017,
Date of refusal: 25/04/2013,, , Revision: 16, Authorised, Last updated: 28/01/2021
-
List item
Human medicine European public assessment report (EPAR): Picato
Ingenol mebutate, Keratosis, Actinic
Date of authorisation: 15/11/2012,, , Revision: 10, Withdrawn, Last updated: 31/07/2020
-
List item
Human medicine European public assessment report (EPAR): Lartruvo
Olaratumab, Sarcoma
Date of authorisation: 09/11/2016,, , 
, 
, Revision: 3, Withdrawn, Last updated: 02/09/2019